Research Topics
Genomes and Genes
| Torsten O NielsenSummaryAffiliation: University of British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancerMartin Buess
Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
Genome Biol 8:R191. 2007..Perturbations in cell-cell interactions are a key feature of cancer. However, little is known about the systematic effects of cell-cell interaction on global gene expression in cancer...
Are triple-negative tumours and basal-like breast cancer synonymous?Emad A Rakha
Breast Cancer Res 9:404; author reply 405. 2007
Use of immunohistochemical markers can refine prognosis in triple negative breast cancerMarc Tischkowitz
Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
BMC Cancer 7:134. 2007..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancerTorsten O Nielsen
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Clin Cancer Res 16:5222-32. 2010....
Translating gene expression into clinical care: sarcomas as a paradigmTorsten O Nielsen
Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
J Clin Oncol 28:1796-805. 2010..Despite challenges in organization and accrual, future clinical trials of sarcomas need to be designed that take into account specific molecular subtypes as distinct diseases...
Small blue round cell tumor of the interosseous membrane bearing a t(2;22)(q34;q12)/EWS-CREB1 translocation: a case reportMarina Pacheco
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
Mol Cytogenet 3:12. 2010..The group of small blue round cell tumors encompasses a heterogeneous group of neoplasms characterized by primitive appearing round cells with few distinguishing histologic features...
Microarray analysis of sarcomasTorsten O Nielsen
British Columbia Cancer Agency, Vancouver Coastal Health Research Institute, and Department of Pathology, University of British Columbia, Canada
Adv Anat Pathol 13:166-73. 2006..Nevertheless, results need to be interpreted in the context of histopathology and validated by complementary technologies and/or other research groups...
Discovery research to clinical trial: a ten year journeyTorsten O Nielsen
Anatomical Pathology, Vancouver Hospital and Health Sciences Ctr, 855 West 12th Avenue, Vancouver, British Columbia
Clin Invest Med 33:E342-8. 2010..Results from exciting, emerging next generation sequencing technologies will need to undergo similar validation and preclinical studies before they can be expected to impact patient care...
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersStephen Chia
Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
J Clin Oncol 26:5697-704. 2008..This study assessed the prognostic impact of HER2 overexpression/amplification in a large series of node-negative breast cancers...
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypesGolareh Habibi
Laboratory for Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
Breast Cancer Res 10:R86. 2008..We therefore investigated whether YB-1 identifies patients at risk for either reduced relapse free survival or decreased r breast cancer specific survival (BCSS) across all tumor subtypes by evaluating 4,049 cases...
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeMaggie C U Cheang
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
Clin Cancer Res 14:1368-76. 2008..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
J Natl Cancer Inst 101:736-50. 2009....
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosisLeah M Prentice
Department of Pathology and Prostate Centre, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Vancouver, BC, Canada V6H 3Z6
Oncogene 24:7281-9. 2005..Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplification. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus...
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patientsShuzhen Liu
Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Center, University of British Columbia, Vancouver, BC, Canada
Breast Cancer Res Treat 119:53-61. 2010..PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone...
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma modelsShuzhen Liu
Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada
Mol Cancer Ther 7:1751-61. 2008..Histone deacetylase inhibitors show promising preclinical activity in multiple clear cell sarcoma models...
MDM2 protein expression is a negative prognostic marker in breast carcinomaDmitry A Turbin
Genetic Pathology Evaluation Centre of the Department of Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
Mod Pathol 19:69-74. 2006..Immunohistochemical studies of MDM2 in more than 2000 breast carcinomas show that MDM2 is an independent negative prognostic marker...
Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcomaAmanda Jagdis
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
Am J Surg Pathol 33:1743-51. 2009....
Breast cancer subtypes and the risk of local and regional relapseK David Voduc
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
J Clin Oncol 28:1684-91. 2010..Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays...
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survivalSam M Wiseman
Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Cancer 103:1770-7. 2005..The objective of the current study was to determine the frequency and the possible prognostic effect of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma...
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survivalMaggie C U Cheang
Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Centre, and University of British Columbia, Vancouver, British Columbia, Canada
J Clin Oncol 24:5637-44. 2006..CONCLUSION: SP1 represents an improved standard for ER immunohistochemistry assessment in breast cancer...
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapyAnna L Stratford
Laboratory for Oncogenomic Research, Department of Pediatrics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
Breast Cancer Res 9:R61. 2007..We pursued this in light of our recent work showing that YB-1 induces the expression of EGFR, a new BLBC marker...
The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotypeDavid Voduc
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
Hum Pathol 39:1431-7. 2008..In conclusion, the combination of high cyclin E and Skp2 expression predicts for poor prognosis in breast cancer in univariate analysis only, it is associated with high risk features, and it is associated with the basal phenotype...
Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probeJefferson Terry
Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Diagn Mol Pathol 14:77-82. 2005..The CISH probes produced signals too weak to interpret. The use of breakapart FISH probes is a relatively quick procedure for detection of synovial sarcoma translocations and can be applied to archival specimens in tissue microarrays...
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancerSimon J Crabb
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Clin Breast Cancer 8:249-56. 2008..We hypothesized that molecular classification based on breast cancer biology would predict the presence of nodal involvement at diagnosis, which might aid treatment decisions regarding the axilla...
Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeuticsLe Su
Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
Cancer Cell 21:333-47. 2012..Together, these studies define a fundamental role for aberrant ATF2 transcriptional dysregulation in the etiology of synovial sarcoma...
Metastatic behavior of breast cancer subtypesHagen Kennecke
Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
J Clin Oncol 28:3271-7. 2010..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
Gene expression profiling of breast cancerMaggie C U Cheang
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia V6H 3Z6, Canada
Annu Rev Pathol 3:67-97. 2008..Prospective trials are now underway to determine the value of such tools for clinical decision making in breast cancer; these efforts may serve as a model for using such approaches in other tumor types...
Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEVTony L Ng
Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada, V5Z 4E6
J Mol Diagn 9:459-63. 2007....
TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studiesJefferson Terry
Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
Am J Surg Pathol 31:240-6. 2007..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer...
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro modelsJefferson Terry
Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Clin Cancer Res 11:5631-8. 2005....
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaTorsten O Nielsen
Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Clin Cancer Res 10:5367-74. 2004..These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients...
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancerAlan I So
The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
Clin Cancer Res 14:6944-54. 2008..This study assesses the effect of IGFBP-2 on the behavior of human breast cancer using clinical specimens as well as in vitro and in vivo experimental systems...
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcomaJoanna M Lubieniecka
The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
Cancer Res 68:4303-10. 2008..Furthermore, our work highlights a possible mechanism behind the efficacy of a clinically applicable HDAC inhibitor in synovial sarcoma treatment...
Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic optionsDavid Voduc
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Clin Breast Cancer 8:S171-8. 2008..Particular emphasis is placed on the clinical implications of basal breast cancer and potential therapeutic options available to oncologists...
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancerShuzhen Liu
Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada
Breast Cancer Res 14:R48. 2012..We conducted this study to assess CD8+ (cytotoxic T) lymphocyte infiltration in a large cohort of invasive early stage breast cancers, and to evaluate its prognostic effect in different breast cancer intrinsic subtypes...
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia
Department of Medical Oncology, British Columbia Cancer Agency, British Columbia, Canada
Clin Cancer Res 18:4465-72. 2012..12) to evaluate the prognostic and predictive significance of intrinsic subtypes identified by both the PAM50 gene set and by immunohistochemistry...
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 casesDmitry A Turbin
Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
Breast Cancer Res Treat 110:417-26. 2008..Our study compares visual scoring of ER in invasive breast cancer by histopathologists to quantitation of staining using a fully automated system...
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycinTorsten O Nielsen
British Columbia Research Institute for Children's and Women's Health, Department of Pediatrics, Laboratory for Oncogenomic Research, University of British Columbia, Vancouver British Columbia, Canada
Cancer Res 64:286-91. 2004..Thus, our study raises the possibility that 17AAG could prove to be an effective therapeutic agent for a large number of breast cancer patients by inhibiting the IGF-IR and ultimately uPA...
YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumorAnna Isphording
Department of Pathology and Laboratory Medicine, and Genetic Pathology Evaluation Center, Vancouver General Hospital, Vancouver, British Columbia, Canada V5Z 4E3
Hum Pathol 44:837-43. 2013....
Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histologyTorsten O Nielsen
Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada
Am J Pathol 163:1449-56. 2003..Digital images from over 2500 immunostained cores analyzed in this study were captured and are made accessible through the accompanying website: http://microarray-pubs.stanford.edu/tma_portal/synsarc...
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangementCheng Han Lee
Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada
Am J Surg Pathol 36:1562-70. 2012..When evaluating high-grade uterine sarcomas, cyclin D1 can be included in the immunohistochemical panel as an indicator of YWHAE-FAM22 ESS...
Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell TumorHongwei Cheng
Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada V5Z 1M9
Sarcoma 2010:174528. 2010..The results from this model support clinical trials of equivalent humanized agents and anti-CSF1R small molecule drugs in cases of tenosynovial giant cell tumor refractory to conventional local therapy...
Tissue microarrays in clinical oncologyDavid Voduc
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Semin Radiat Oncol 18:89-97. 2008..This review describes the impact of TMA-based research in clinical oncology and its potential future applications. Technical aspects of TMA construction and the advantages and disadvantages inherent to this technology are also discussed...
Nuclear beta-catenin in mesenchymal tumorsTony L Ng
Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada
Mod Pathol 18:68-74. 2005..High-level nuclear beta-catenin staining serves as a useful diagnostic tool, as it is specific to a small subset of mesenchymal tumors...
Histone deacetylase 1 and 2 in mesenchymal tumorsMarina Pacheco
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
Mod Pathol 25:222-30. 2012....
Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literatureAnna F Lee
Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia V5Z1M9, Canada
Hum Pathol 42:1804-9. 2011..This case demonstrates the value of having a distinctive confirmatory molecular pathology test for diagnosis and expands our knowledge of the histologic variants possible in low-grade fibromyxoid sarcoma...
Molecular characterisation of soft tissue tumours: a gene expression studyTorsten O Nielsen
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
Lancet 359:1301-7. 2002..Large numbers of uncharacterised genes contributed to distinctions between the tumours, and some of these could be useful markers for diagnosis, have prognostic significance, or prove possible targets for treatment...
Duodenal epithelioid gastrointestinal stromal tumor with prominent granular cell featuresAnna Adamiak
Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada
Hum Pathol 40:599-602. 2009..The current case illustrates the importance of considering gastrointestinal stromal tumor in the differential diagnosis of any epithelioid tumors in the gastrointestinal tract or the abdominal-pelvic cavity...
Kaposi sarcoma of the adrenal gland resembling epithelioid angiosarcoma: a case reportHassan Huwait
Anatomical Pathology JP1401, Vancouver Hospital, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada
Sarcoma 2011:898257. 2011..Immunohistochemistry for human herpes virus-8 was strongly positive in the tumor cells. To the best of our knowledge, this is the first report of an anaplastic Kaposi sarcoma in the adrenal gland...
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq dataAndrew McPherson
Centre for Translational and Applied Genomics, BC Cancer Agency, Vancouver, British Columbia, Canada
PLoS Comput Biol 7:e1001138. 2011....
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcomaAnne Nguyen
Jack Bell Research Centre, Vancouver Coastal Health Research Institute, The University of British Columbia, 553 2660 Oak Street, Vancouver, BC, Canada V6H3Z6
Sarcoma 2009:794901. 2009..Additionally, we find that the NF-kappaB inhibitor BAY 11-7085 synergizes with MS-275. We conclude that agents inhibiting NF-kappaB synergize with HDAC inhibitors against synovial sarcoma...
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinomaNikita A Makretsov
Genetic Pathology Evaluation Centre of the Department of Pathology, and Prostate Research Centre of Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Canada
Clin Cancer Res 10:6143-51. 2004..This work demonstrates that hierarchical clustering of immunostaining data by using multiple markers can group breast cancers into classes with clinical relevance and is superior to the use of individual prognostic markers...
Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the boneCheng Han Lee
Department of Pathology, Stanford University, Stanford, CA, USA
Mod Pathol 21:531-9. 2008..These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB...
Determination of stromal signatures in breast carcinomaRobert B West
Department of Pathology, Stanford University Medical Center, Stanford, California, USA
PLoS Biol 3:e187. 2005..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...
The gene expression profile of extraskeletal myxoid chondrosarcomaSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
J Pathol 206:433-44. 2005..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC...
Prognostic significance of macrophage infiltration in leiomyosarcomasCheng Han Lee
Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
Clin Cancer Res 14:1423-30. 2008..Their presence is associated with poor clinical outcome in a variety of epithelial malignancies. The aim of this study is to examine the prognostic significance of tumor-associated macrophages in sarcomas...
FOXA1 expression in breast cancer--correlation with luminal subtype A and survivalSunil Badve
Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
Clin Cancer Res 13:4415-21. 2007..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
cDNA microarray-based translational research in soft tissue sarcomaJoanna M Lubieniecka
J Surg Oncol 92:267-71. 2005..Recent results in synovial sarcoma are used to highlight the applicability of this technology for marker and target discovery, as well as the need for preclinical validation of putative therapeutic targets...
Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberansSabine C Linn
Departments of Pathology, Genetics, and Biochemistry, and Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, California 94305, USA
Am J Pathol 163:2383-95. 2003....
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring
Applied Genomics Inc, 863 Mitten Rd #103, Burlingame, CA, USA
J Clin Oncol 24:3039-47. 2006..CONCLUSION: A panel of five antibodies can significantly improve on traditional prognosticators in predicting outcome for ER-positive breast cancer patients...
Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberansRobert B West
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Am J Surg Pathol 28:1063-9. 2004..stanford.edu/tma_portal/apod/). We conclude that Apo D is strongly expressed in DFSPs and neural lesions and may be useful in differentiating DFSP from fibrous histiocytoma...
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusRobert B West
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Am J Pathol 165:107-13. 2004..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase...
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistryForrest D Hsu
Department of Pathology and Genetic Pathology Evaluation Centre, Vancouver General Hospital and the University of British Columbia, Canada
Mod Pathol 15:1374-80. 2002....
Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitidesJohn S Cupp
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Am J Surg Pathol 31:970-6. 2007....
CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' replyJay S Wunder
University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Lancet Oncol 8:668-9. 2007
Diagnostic and prognostic markers for gastrointestinal stromal tumors in NorwaySonja E Steigen
Department of Pathology, Institute of Medical Biology, University of Tromsø, Norway
Mod Pathol 21:46-53. 2008..Expression of p16 was significantly correlated with unfavorable prognosis, whereas L1 expression was not...
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Oncogene 23:7780-90. 2004..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
Deconstructing the molecular portrait of basal-like breast cancerFruma Yehiely
Cell Death Regulation Laboratory, Departments of Medicine and Cell and Molecular Biology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Trends Mol Med 12:537-44. 2006..Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors...
TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarraysChih Long Liu
Biological and Biomedical Sciences Program, Division of Medical Sciences, Harvard Medical School, Cambridge, MA 02138, USA
Mod Pathol 18:1641-8. 2005..This greatly facilitates analysis of tissue microarrays, particularly for users with large repositories of data, and may facilitate discovery of biological trends and help refine diagnostic accuracy of tissue markers in clinical samples...
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancerJose V Moyano
Cell Death Regulation Laboratory, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
J Clin Invest 116:261-70. 2006..Our data also implicate the MEK/ERK pathway as a potential therapeutic target for these tumors...
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy
Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
Clin Cancer Res 12:2468-75. 2006..We validated the results in an independent series. Experimental Design and..
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyLisa A Carey
Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
JAMA 295:2492-502. 2006..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
Opportunities for improving the therapeutic ratio for patients with sarcomaJay S Wunder
University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
Lancet Oncol 8:513-24. 2007..Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future...
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumorsInigo Espinosa
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Am J Surg Pathol 32:210-8. 2008..5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT...
